相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia
Federico Gaiti et al.
NATURE (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity
S. Marsilio et al.
LEUKEMIA (2018)
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
F. Nadeu et al.
LEUKEMIA (2018)
NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways
D. Benedetti et al.
LEUKEMIA (2018)
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
J. R. Brown et al.
LEUKEMIA (2018)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Susan O'Brien et al.
BLOOD (2018)
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials
Jeffrey Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics
Gian Matteo Rigolin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations
Andreas Agathangelidis et al.
HAEMATOLOGICA (2018)
Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia
Idanna Innocenti et al.
HEMATOLOGICAL ONCOLOGY (2018)
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Jeffrey A. Jones et al.
LANCET ONCOLOGY (2018)
The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia
Renee Beekman et al.
NATURE MEDICINE (2018)
Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy
Jan A. Burger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D. Herling et al.
NATURE COMMUNICATIONS (2018)
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations
Andreas Agathangelidis et al.
HAEMATOLOGICA (2018)
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
Paula Cramer et al.
LANCET ONCOLOGY (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Jan A. Burger et al.
NATURE REVIEWS CANCER (2018)
Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
Lijian Yu et al.
CLINICAL CANCER RESEARCH (2017)
Antigen receptor stereotypy in chronic lymphocytic leukemia
K. Stamatopoulos et al.
LEUKEMIA (2017)
Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome
S. Barrio et al.
LEUKEMIA (2017)
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
Iris de Weerdt et al.
HAEMATOLOGICA (2017)
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Genetic landscape and deregulated pathways in B-cell lymphoid malignancies
R. Rosenquist et al.
JOURNAL OF INTERNAL MEDICINE (2017)
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components
F. Pozzo et al.
LEUKEMIA (2017)
Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia
Giulia Fabbri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia
Phillip J. Law et al.
NATURE COMMUNICATIONS (2017)
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
Dan A. Landau et al.
NATURE COMMUNICATIONS (2017)
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
Iris de Weerdt et al.
HAEMATOLOGICA (2017)
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
Jeffrey A. Jones et al.
LANCET HAEMATOLOGY (2017)
A critical epithelial survival axis regulated by MCL-1 maintains thymic function in mice
Reema Jain et al.
BLOOD (2017)
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib
Cecelia R. Miller et al.
BLOOD ADVANCES (2017)
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Kirsten Fischer et al.
BLOOD (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
A nationwide population-based cross-sectional comparison of hematological malignancies incidences between Taiwan and the United States of America
Shang-Ju Wu et al.
ANNALS OF HEMATOLOGY (2016)
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
Philip A. Thompson et al.
BLOOD (2016)
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Kirsten Fischer et al.
BLOOD (2016)
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations
Viktor Ljungstrom et al.
BLOOD (2016)
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation
F. Pozzo et al.
LEUKEMIA (2016)
Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibility
Lynn R. Goldin et al.
BLOOD (2016)
Clinical impact of MYD88 mutations in chronic lymphocytic leukemia
Alejandra Martinez-Trillos et al.
BLOOD (2016)
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia
Ferran Nadeu et al.
BLOOD (2016)
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
Carmen Diana Herling et al.
BLOOD (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
Lili Wang et al.
CANCER CELL (2016)
A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
Nisar A. Amin et al.
CLINICAL CANCER RESEARCH (2016)
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
Michael Hallek
LANCET ONCOLOGY (2016)
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer et al.
LANCET ONCOLOGY (2016)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Richter syndrome: pathogenesis and management
Davide Rossi et al.
SEMINARS IN ONCOLOGY (2016)
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Jan A. Burger et al.
NATURE COMMUNICATIONS (2016)
The molecular pathogenesis of chronic lymphocytic leukaemia
Giulia Fabbri et al.
NATURE REVIEWS CANCER (2016)
The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Laura Belver et al.
NATURE REVIEWS CANCER (2016)
Prognostic relevance of MYD88 mutations in CLL: the jury is still out
Panagiotis Baliakas et al.
BLOOD (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification
Paolo Strati et al.
BLOOD (2015)
Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
Larry Mansouri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2015)
Mutations driving CLL and their evolution in progression and relapse
Dan A. Landau et al.
NATURE (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution
S. Kasar et al.
NATURE COMMUNICATIONS (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Recurrent mutations refine prognosis in chronic lymphocytic leukemia
P. Baliakas et al.
LEUKEMIA (2015)
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer et al.
BLOOD (2014)
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome
Alejandra Martinez-Trillos et al.
BLOOD (2014)
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness
Monica Messina et al.
BLOOD (2014)
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2014)
Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CANCER CELL (2014)
Immunogenetic Studies of Chronic Lymphocytic Leukemia: Revelations and Speculations about Ontogeny and Clinical Evolution
Anna Vardi et al.
CANCER RESEARCH (2014)
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia
F. Arruga et al.
LEUKEMIA (2014)
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
S. Jeromin et al.
LEUKEMIA (2014)
Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression
J. Ojha et al.
LEUKEMIA (2014)
The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia
Tatjana Stankovic et al.
LEUKEMIA & LYMPHOMA (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
Frederik Damm et al.
CANCER DISCOVERY (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2013)
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial
David G. Oscier et al.
BLOOD (2013)
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Ekaterina Chigrinova et al.
BLOOD (2013)
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
Peter Dreger et al.
BLOOD (2013)
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
[Anonymous]
BLOOD (2013)
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL
Anna Vardi et al.
BLOOD (2013)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
Giulia Fabbri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia
L. Mansouri et al.
LEUKEMIA (2013)
NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
N. Villamor et al.
LEUKEMIA (2013)
Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients
S. Weissmann et al.
LEUKEMIA (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia
Andrew J. Ramsay et al.
NATURE GENETICS (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
Winston Timp et al.
NATURE REVIEWS CANCER (2013)
NOTCH1 mutations in CLL associated with trisomy 12
Veronica Balatti et al.
BLOOD (2012)
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
Andreas Agathangelidis et al.
BLOOD (2012)
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia Are They the Same Disease?
Fabio P. S. Santos et al.
CANCER JOURNAL (2012)
NOTCH1 mutations in+12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of+12 CLL
Ilaria Del Giudice et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Kate Cwynarski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial
Anna Skowronska et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cellular origin and pathophysiology of chronic lymphocytic leukemia
Marc Seifert et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
Marcus Duehren-von Minden et al.
NATURE (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
Victor Quesada et al.
NATURE GENETICS (2012)
Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia
Marta Kulis et al.
NATURE GENETICS (2012)
The Notch signalling system: recent insights into the complexity of a conserved pathway
K. G. Guruharsha et al.
NATURE REVIEWS GENETICS (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Xavier C. Badoux et al.
BLOOD (2011)
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma
Davide Rossi et al.
BLOOD (2011)
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness
Davide Rossi et al.
BLOOD (2011)
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
Davide Rossi et al.
BLOOD (2011)
Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Human Chronic Lymphocytic Leukemia
Yoshikane Kikushige et al.
CANCER CELL (2011)
Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia
Martin Trbusek et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
David Gonzalez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
Giulia Fabbri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
CLL-like B-lymphocytes are systematically present at very low numbers in peripheral blood of healthy adults
J. Almeida et al.
LEUKEMIA (2011)
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2011)
Prognostic factors in chronic lymphocytic leukemia-what do we need to know?
Paula Cramer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
13q14 deletions in CLL involve cooperating tumor suppressors
Alexey Palamarchuk et al.
BLOOD (2010)
The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect
Shang-Ju Wu et al.
BLOOD (2010)
The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia
Ulf Klein et al.
CANCER CELL (2010)
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management
T. D. Shanafelt et al.
LEUKEMIA (2010)
Therapeutic antibody targeting of individual Notch receptors
Yan Wu et al.
NATURE (2010)
The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring
Antonis Dagklis et al.
BLOOD (2009)
Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience
Pau Abrisqueta et al.
BLOOD (2009)
Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach
Wendy G. Nieto et al.
BLOOD (2009)
Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
Francesc Bosch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia
Ola Landgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia:: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression
Tait D. Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
Andy C. Rawstron et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL
B Austen et al.
BLOOD (2005)
miR-15 and miR-16 induce apoptosis by targeting BCL2
A Cimmino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Characterization of a novel B-CLL candidate gene -: DLEU7 -: located in the 13q14 tumor suppressor locus
M Hammarsund et al.
FEBS LETTERS (2004)
Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database
LR Goldin et al.
BLOOD (2004)
Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vλ2-14 gene use and homologous CDR3s:: implicating recognition of a common antigen epitope
G Tobin et al.
BLOOD (2003)
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia
M Crespo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
GA Calin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells
U Klein et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia
A Rosenwald et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia
A Migliazza et al.
BLOOD (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Age-dependent changes in B lymphocyte development in man and mouse
P Ghia et al.
EXPERIMENTAL GERONTOLOGY (2000)
分享论文
